Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein
Abstract In this study, a novel theranostic radiopharmaceutical, [13xLa]La-FAP-2286, for targeting Fibroblast Activation Protein (FAP)-positive tumors. The theranostic pair of 132La (half-life: 4.59 h, 42.1% β⁺) and 135La (half-life: 18.91 h, 100% EC) was produced via proton bombardment of natural b...
Saved in:
| Main Authors: | Ali Shirpour, Asghar Hadadi, Samaneh Zolghadri, Sara Vosoughi, Saeed Rajabifar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-91716-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Specific reaction conditions for efficient automated 68Ga-radiolabeling of the FAP-2286 pseudopeptide on a GAIA® synthesizer
by: Maissa Ammour, et al.
Published: (2025-07-01) -
In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluation
by: Circe D. van der Heide, et al.
Published: (2024-12-01) -
The Development of Al<sup>18</sup>F-NOTA-FAP-2286 as an FAP-Targeted PET Tracer and the Translational Application in the Diagnosis of Acquired Drug Resistance in Progressive Prostate Cancer
by: Xia Du, et al.
Published: (2025-04-01) -
Preclinical evaluation of [68Ga]Ga-AAZTA-FAPI-46: a novel PET tracer for targeting fibroblast activation protein (FAP)
by: Rebecca Rizzo, et al.
Published: (2025-08-01) -
Enhanced contrast in FAP-targeting PET imaging with 61Cu-labeled FAP inhibitors: development and preclinical evaluation of novel [61Cu]Cu-Kalios PET radioligands
by: Jacopo Millul, et al.
Published: (2025-08-01)